26/5/6938



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Stéphane CHEVALLIER

Group Art Unit

(Unassigned)

Application No.

(Natl. Phase of PCT/FR2004/002654)

Examiner

(Unassigned)

Filed

(Herewith)

Docket No.

13415/104015

For

PROTECTED INJECTION SYRINGE DEVICE

INFORMATION DISCLOSURE STATEMENT

COMMISSIONER FOR PATENTS Customer Service Window Randolph Bldg. 401 Dulany Street Alexandria, VA 22314

Sir:

Pursuant to 37 CFR § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). The paragraphs marked below are applicable. It is believed that no fees other than those indicated below are due, but authorization is hereby given to charge any additional fees due, or to credit any overpayment, to deposit account 11-0600.

- 1. This Information Disclosure Statement is being filed (a) within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. §1.53(d), (b) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, (c) before the mailing date of a first Office Action on the merits in the present application, OR (d) before the mailing of a first office action after filing of a request for continued examination. No certification or fee is required.
- 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a final action, Notice of Allowance, or any action that otherwise closes prosecution.

	a. I hereby certify that each item of information contained in this information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
	b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
	c. Please debit Deposit Account No. 11-0600 in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p) to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached. 37 CFR §1.97(c)(2).
prosecthat the Accoung 37 CF	This Information Disclosure Statement is being filed after the mailing a final action, Notice of Allowance or an action that otherwise closes ution, but before payment of the Issue Fee. Applicant(s) hereby request(s) Information Disclosure Statement be considered. Please debit Deposit It No. 11-0600 in the amount of \$180.00 in payment of the petition fee under \$\frac{1}{2}\$ \frac{1}{2}\$ \frac{1}{2}\$ (p) to ensure consideration of the disclosed information. Two duplicate of this paper are attached.
	a. I hereby certify that each item of information contained in this nformation Disclosure Statement was first cited in any communication from a foreign patent office in any counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
	b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
□ preser	1. Relevance of the non-English language reference(s) is discussed in the specification.
	The reference(s) was/were cited in a counterpart foreign application. lish language version of the foreign search report is attached for the er's information.
	6. A concise explanation of the relevance of certain non-English language ce(s) appears in the Appendix attached hereto.
matter	7. The Examiner's attention is directed to co-pending U.S. Patent tion No, filed, which is directed to related technical subject The identification of this U.S. Patent Application is not to be construed as a of secrecy as to that application now or upon issuance of the present

.../ 5/0938

application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination of the present application. This application is one of a series of related applications adenuified in 1006 the attached Appendix, which are directed to related technical subject matter. The identification of those U.S. Patent Applications is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during the examination. The reference(s) was/were cited by or submitted to the Office in parent application No._____, filed _____, which is relied upon for an earlier filing date under 35 U.S.C. §120. Thus, copies of these references are not attached. 37 CFR §1.98(d). \square 10. English-language Abstracts of the non-English language references are attached hereto. ightharpoons11. Copies of U.S. references are not required. 12. Other: The references were cited in the International Search Report, a $\overline{\mathbf{A}}$ copy of which is enclosed. Respectfully submitted, Date: 24 April 2006 David J. Zibelli (Reg. No. 32,394) **KENYON & KENYON LLP** 1500 K Street, N.W. Washington, D.C. 20005 Telephone: (202) 220-4200

Facsimile: (202) 220-4201

Approved for use through 07/31/2006, OMB-0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
and to respond to a collection of information unless that the collection of information unless than the collection of the collection of information unless than the collection of the

13415/104015

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Attorney Docket Number

Substitute for form 1449A/PTO

Application Number

(Natl. Phase of PCT/FR04/02654)

Filing Date

(Herewith)

First Named Inventor

(Use as many sheets as necessary)

(Use as many sheets as necessary)

Complete if Known © 2 2 3

Application Number

(Natl. Phase of PCT/FR04/02654)

Filing Date

(Herewith)

Stephane CHEVALLIER

Art Unit

(Unassigned)

Examiner Name

(Unassigned)

Sheet

U.S. PATENT DOCUMENTS						
Examiner	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials *		Number - Kind Code ² (if known)			Passages or Relevant Figures Appear	
	1	US-6,319,234 B1	11/20/01	RESTELLI et al.		
		·- ··				
		-				
		US-				
	·	US-				
•		US-	. <u>-</u>			
		US-				
		US-				
		US-				
		US-			-	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	i
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Date MM-DD-YYYY	Applicant of Cited Document		T ⁶
	1	WO 98/35714	08/20/98	RESTELLI et al.		
	2	WO 02/072182 A1	09/19/02	GLENORD PTY LTD		
	3	FR 2 653 667	05/03/91	FLOQUET, N.		
	4	FR 2 835 753	08/15/03	PLASTEF INVESTISSEM ENTS SA		
						· -
	L	l				

1		-		0.4	 	
	Examiner			Date		
L	Signature		+	Considered		
•		l			 	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.